139 related articles for article (PubMed ID: 35524758)
1. Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Choy E; Cote GM; Michaelson MD; Wirth L; Gainor JF; Muzikansky A; Sequist LV; Sullivan RJ; Fidias PM; Shaw A; Heist RS
Oncologist; 2022 Jul; 27(7):600-606. PubMed ID: 35524758
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Xu J; Higgins MJ; Tolaney SM; Come SE; Smith MR; Fornier M; Mahmood U; Baselga J; Yeap BY; Chabner BA; Isakoff SJ
Oncologist; 2020 Aug; 25(8):652-660. PubMed ID: 32463152
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Leone JP; Duda DG; Hu J; Barry WT; Trippa L; Gerstner ER; Jain RK; Tan S; Lawler E; Winer EP; Lin NU; Tolaney SM
Breast Cancer Res Treat; 2020 Jan; 179(1):113-123. PubMed ID: 31541381
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
8. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
[TBL] [Abstract][Full Text] [Related]
9. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.
Yavuz S; Apolo AB; Kummar S; del Rivero J; Madan RA; Shawker T; Reynolds J; Celi FS
Thyroid; 2014 Aug; 24(8):1223-31. PubMed ID: 24724719
[TBL] [Abstract][Full Text] [Related]
14. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report.
Schallier D; Lesfevre P; Everaert H
Anticancer Res; 2020 Apr; 40(4):2265-2269. PubMed ID: 32234924
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N; McGregor B; Maughan BL; Dorff TB; Kelly W; Fang B; McKay RR; Singh P; Pagliaro L; Dreicer R; Srinivas S; Loriot Y; Vaishampayan U; Goel S; Curran D; Panneerselvam A; Schwickart M; Choueiri TK; Pal S
Lancet Oncol; 2022 Jul; 23(7):899-909. PubMed ID: 35690072
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
Smith DC; Daignault-Newton S; Grivas P; Reichert ZR; Hussain M; Cooney KA; Caram M; Alva A; Jacobson J; Yablon C; Mehra R; Escara-Wilke J; Shelley G; Keller ET
Clin Genitourin Cancer; 2020 Aug; 18(4):332-339.e2. PubMed ID: 32299729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
